SCHEMBL3085443

SCHEMBL3085443

CC(C)N(C(=O)C(Cc1cccc(C(F)(F)F)c1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1)c1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 10/20 0.49
KAT6A Q92794 1/20 0.46
LARS1 Q9P2J5 1/20 0.43
PIN1 Q13526 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
F2 P00734 1/20 0.40
HTR2A P28223 2/20 0.40
HTR2C P28335 2/20 0.40
HTR7 P34969 1/20 0.40
NR1I2 O75469 1/20 0.38
ADRB1 P08588 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
CHRM3 P20309 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102827 0.91 MEN1 (0.50) KAT6ALARS1PIN1MEN1KMT2A
SCHEMBL3096954 0.88 LARS1 (0.45) KAT6ALARS1MEN1KMT2AF2
SCHEMBL3092646 0.86 KAT6A (0.46) KAT6ALARS1PIN1MEN1KMT2A
SCHEMBL3101068 0.84 LARS1 (0.46) KAT6ALARS1MEN1KMT2AF2
SCHEMBL3087740 0.82 LARS1 (0.44) KAT6ALARS1MEN1KMT2AF2
SCHEMBL3097728 0.82 LARS1 (0.59) KAT6ALARS1MEN1KMT2AF2
SCHEMBL3103710 0.81 KAT6A (0.47) PPARGKAT6ALARS1MEN1KMT2A
SCHEMBL3091586 0.81 CYP3A4 (0.40) PIN1KMT2AHTR2AHTR2CNR1I2
SCHEMBL3080156 0.81 USP30 (0.49) KAT6ALARS1MEN1KMT2AF2
SCHEMBL3091579 0.81 CYP3A4 (0.40) PIN1KMT2AHTR2AHTR2CNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 PPARG 136/4885KAT6A 3337/4885LARS1 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.